JP2023515687A5 - - Google Patents

Info

Publication number
JP2023515687A5
JP2023515687A5 JP2022552626A JP2022552626A JP2023515687A5 JP 2023515687 A5 JP2023515687 A5 JP 2023515687A5 JP 2022552626 A JP2022552626 A JP 2022552626A JP 2022552626 A JP2022552626 A JP 2022552626A JP 2023515687 A5 JP2023515687 A5 JP 2023515687A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
composition according
met
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022552626A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023515687A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/020255 external-priority patent/WO2021178296A1/en
Publication of JP2023515687A publication Critical patent/JP2023515687A/ja
Publication of JP2023515687A5 publication Critical patent/JP2023515687A5/ja
Pending legal-status Critical Current

Links

JP2022552626A 2020-03-02 2021-03-01 大環状化合物の治療使用 Pending JP2023515687A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062984159P 2020-03-02 2020-03-02
US62/984,159 2020-03-02
PCT/US2021/020255 WO2021178296A1 (en) 2020-03-02 2021-03-01 Therapeutic uses of macrocyclic compounds

Publications (2)

Publication Number Publication Date
JP2023515687A JP2023515687A (ja) 2023-04-13
JP2023515687A5 true JP2023515687A5 (https=) 2024-03-07

Family

ID=77613771

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022552626A Pending JP2023515687A (ja) 2020-03-02 2021-03-01 大環状化合物の治療使用

Country Status (11)

Country Link
US (1) US20250262216A1 (https=)
EP (1) EP4114530A4 (https=)
JP (1) JP2023515687A (https=)
KR (1) KR20230022151A (https=)
CN (1) CN115397514A (https=)
AU (1) AU2021229457A1 (https=)
BR (1) BR112022017425A2 (https=)
CA (1) CA3174455A1 (https=)
IL (1) IL295938A (https=)
MX (1) MX2022010945A (https=)
WO (1) WO2021178296A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111902417B (zh) 2018-04-25 2023-07-28 北京普祺医药科技股份有限公司 一种二芳基巨环化合物、药物组合物以及其用途
US20240132517A1 (en) * 2021-02-10 2024-04-25 Goharmony Therapeutics (Shenzhen) Co., Ltd. Macrocyclic compound, pharmaceutical composition, and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
ES2933350T3 (es) * 2014-01-24 2023-02-06 Turning Point Therapeutics Inc Macrociclos de diarilo como moduladores de proteína quinasas
RU2765181C2 (ru) * 2015-07-06 2022-01-26 Тёрнинг Поинт Терапьютикс, Инк. Полиморфная форма диарильного макроцикла
US10689400B2 (en) * 2016-07-28 2020-06-23 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
CN111182903A (zh) * 2017-07-28 2020-05-19 特普医药公司 巨环化合物及其用途
CN114423762B (zh) * 2019-09-30 2024-03-29 浙江海正药业股份有限公司 大环类衍生物及其制备方法和用途

Similar Documents

Publication Publication Date Title
JP2022058395A5 (https=)
JP2023168298A5 (https=)
JP2022532790A5 (https=)
JP2013064024A5 (https=)
JP2024506612A5 (https=)
JPWO2023190748A5 (https=)
JP2016528162A5 (https=)
JP2020508302A5 (https=)
JP2023539715A5 (https=)
JP2021512131A5 (https=)
RU2020114632A (ru) Терапевтические способы, относящиеся к ингибиторам hsp90
JP2020519672A5 (https=)
JP2020527139A5 (https=)
JP2015232006A5 (https=)
JP2021534158A5 (https=)
JP2013505249A5 (https=)
JP2013126979A5 (https=)
JP2017512791A5 (https=)
JP2019533981A5 (https=)
JP2023515687A5 (https=)
JP2021513536A5 (https=)
JP2023545096A5 (https=)
JP2011126896A5 (https=)
JP2017526662A5 (https=)
JP2019511564A5 (https=)